biomarker-trends-header.png

Biomarker Strategic Planning  and Literature review

We announced our new literature-focused features in our last blog post. One of the unique features of our approach is that we use deep learning concepts, a subset of machine learning, to text mine literature. A characteristic of deep learning is that various characteristics, or attributes, of a ...

New Pre-clinical Biomarker Coverage

We are excited to announce improvements to BiomarkerBase, increasing the coverage and analysis of literature. We've added biomarkers sourced only from literature, representing biomarkers in an earlier stage of development.  With this addition there are two main benefits:

Mary Meeker and Amplion Analysis

When building a company, especially a startup, you look forward to moments that change your trajectory. So, when Mary Meeker included our analysis in her annual Internet trends presentation, it got us thinking.

March 2017 Safety Biomarkers and Pharmacovigilance Webinar

Yesterday we completed part 2 of our Safety Biomarkers and Pharmacovigilance webinar. 

Fail Early, Fail Fast - And Increase Likelihood-of-Approval

What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how it affects the industry.

   

March

Webinar: 

Pharmacovigilance and Safety Biomarkers

RECORDING
New Call-to-action
FREE REPORT

Subscribe for Updates

Download our Free IVD Trends Report